Covid-19 roundup: EMA begins rolling review of first Chinese vaccine; After 100% efficacy trial, teenagers could be eligible for Pfizer's vaccine next week
Sinovac’s shot — which was just effective enough to meet regulatory standards — is now the first Chinese Covid-19 vaccine to be considered by the European Medicines Agency.
The EMA’s human medicines committee (CHMP) said on Tuesday that it’s kicking off a rolling review of the inactivated vaccine, dubbed CoronaVac in some regions, in an attempt to speed up the regulatory process. The agency will look at data as they become available to determine whether the benefits of the jab outweigh the risks.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
